Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kronos Bio (KRON)
NASDAQ:KRON
Holding KRON?
Track your performance easily
KRON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.69 - $1.60
Previous Close$0.97
Volume180.15K
Average Volume (3M)257.41K
Market Cap
$60.34M
Enterprise Value-$40.45M
Total Cash (Recent Filing)$124.86M
Total Debt (Recent Filing)$25.80M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Mar 19, 2025EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding60,340,918
10 Day Avg. Volume389,989
30 Day Avg. Volume257,411
Standard Deviation0.19
R-Squared0.19
Alpha-0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.53
Price to Sales (P/S)6.10
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-4.09
Enterprise Value/Gross Profit-6.43
Enterprise Value/Ebitda0.48
Forecast
1Y Price Target
$1.00Price Target Upside-0.50% Downside
Rating ConsensusHold
Number of Analyst Covering2
Kronos Bio News
PremiumCompany Announcements
Kronos Bio Ends Collaboration with Genentech and Roche
PremiumCompany Announcements
Kronos Bio Restructures Workforce and Leadership
Bulls Say, Bears Say
Bulls Say
Expense ReductionKronos plans to implement significant expense reduction strategies, aiming to enhance financial efficiency while exploring various strategic alternatives.
Preclinical DevelopmentsKronos will present preclinical data for KB-7898, demonstrating its potential in reducing auto-antibodies and inflammatory cytokines related to autoimmune diseases.
Strategic AlternativesKronos is exploring strategic alternatives, including potential acquisitions, mergers, or sales of assets to maximize stakeholder value.
Bears Say
Clinical DevelopmentKronos announced the decision to halt clinical development of its lead candidate CDK9i KB-0742 (istisociclib) due to an unfavorable safety-benefit profile.
Safety ConcernsOut of 7 enrolled PROC patients, 5 exhibited neurological events ranging from Grade 1-3 in severity, with symptoms including involuntary movements, confusion, and hallucinations.
Strategic ChallengesKronos may be unable to advance novel candidates into the clinic or enter new partnerships.
---
Ownership Overview
27.67% Insiders
4.10% Mutual Funds
17.76% Other Institutional Investors
47.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KRON FAQ
What was Kronos Bio’s price range in the past 12 months?
Kronos Bio lowest stock price was $0.69 and its highest was $1.60 in the past 12 months.
What is Kronos Bio’s market cap?
Currently, no data Available
When is Kronos Bio’s upcoming earnings report date?
Kronos Bio’s upcoming earnings report date is Mar 19, 2025 which is in 70 days.
How were Kronos Bio’s earnings last quarter?
Kronos Bio released its earnings results on Nov 13, 2024. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.278 by $0.048.
Is Kronos Bio overvalued?
According to Wall Street analysts Kronos Bio’s price is currently Overvalued.
Does Kronos Bio pay dividends?
Kronos Bio does not currently pay dividends.
What is Kronos Bio’s EPS estimate?
Kronos Bio’s EPS estimate is -$0.29.
How many shares outstanding does Kronos Bio have?
Kronos Bio has 60,340,920 shares outstanding.
What happened to Kronos Bio’s price movement after its last earnings report?
Kronos Bio reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.278. Following the earnings report the stock price went down -3.409%.
Which hedge fund is a major shareholder of Kronos Bio?
Among the largest hedge funds holding Kronos Bio’s share is Wildcat Capital Management, Llc. It holds Kronos Bio’s shares valued at 1M.
---
Kronos Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (-0.50% Downside)
$1.00 (-0.50% Downside)
Blogger Sentiment
Bullish
KRON Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 309.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.29%
12-Months-Change
Fundamentals
Return on Equity
-59.08%
Trailing 12-Months
Asset Growth
-36.96%
Trailing 12-Months
Company Description
Kronos Bio
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.
---
KRON Stock 12 Month Forecast
Average Price Target
$1.00
▼(-0.50% Downside)
Technical Analysis
Best Analysts Covering KRON
1 Year
1 Year Success Rate
1/14 ratings generated profit
1 Year Average Return
-29.23%
reiterated a buy rating 5 months ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 7.14% of your transactions generating a profit, with an average return of -29.23% per trade.
---